Tonix Pharmaceuticals Holding (TNXP) Cash from Investing Activities (2011 - 2026)

Tonix Pharmaceuticals Holding's Cash from Investing Activities history runs 16 years deep, the most recent figure standing at -$1.7 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 28100.0% year-over-year to -$1.7 million in Q1 2026; TTM through Mar 2026 was -$6.2 million, a 34422.22% decrease from a year earlier, with the FY2025 full-year figure at -$4.5 million, down 3673.33% from the prior year.
• Cash from Investing Activities retreated to -$1.7 million in Q1 2026 per TNXP's latest filing, from -$1.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at -$3000.0 in Q4 2024 and bottomed at -$24.0 million in Q2 2023.
• The 5-year median for Cash from Investing Activities is -$1.4 million (2025), against an average of -$5.2 million.
• Across the five-year window, Cash from Investing Activities jumped 99.3% in 2024 and sank 33933.33% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$4.7 million in 2022, then jumped by 90.77% to -$431000.0 in 2023, then soared by 99.3% to -$3000.0 in 2024, then sank by 33933.33% to -$1.0 million in 2025, then plunged by 65.72% to -$1.7 million in 2026.
• Per Business Quant, the three latest TNXP Cash from Investing Activities figures stand at -$1.7 million (Q1 2026), -$1.0 million (Q4 2025), and -$962000.0 (Q3 2025).